FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Furlow Brenda S. 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP - General Counsel
(Last)         (First)         (Middle)
614 MCKINLEY PLACE NE
3. Date of Earliest Transaction (MM/DD/YYYY)
5/28/2020
(Street)
MINNEAPOLIS, MN 55413
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  5/28/2020    M    5995  A $108.49  8706  D 
 
Common Stock  5/28/2020    M    1600  A $94.35  10306  D 
 
Common Stock  5/28/2020    S    2195  D $259.7172 (1) 8111  D 
 
Common Stock  5/28/2020    S    3800  D $260.3825 (2) 4311  D 
 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy)  $94.35  5/28/2020    M        1600    (4) 8/12/2021  Common Stock  1600  $0  0  D 
 
Stock Options (Right to Buy)  $108.49  5/28/2020    M        5995    (4) 8/7/2022  Common Stock  5995  $0  10000  D 
 
Stock Options (Right to Buy)  $106.59                   (4) 8/18/2023  Common Stock  10857    10857  D 
 
Stock Options (Right to Buy)  $106.59                   (8) 8/18/2023  Common Stock  14476    14476  D 
 
Restricted Stock Units   (3)                  (11)  (11) Common Stock  1724    1724  D 
 
Stock Options (Right to Buy)  $125.05                   (11) 8/9/2024  Common Stock  9503    9503  D 
 
Stock Options (Right to Buy)  $125.05                   (6) 8/9/2024  Common Stock  12670    12670  D 
 
Restricted Stock Units   (3)                  (10)  (10) Common Stock  1374    1374  D 
 
Stock Options (Right to Buy)  $177.32                   (10) 8/8/2025  Common Stock  7339    7339  D 
 
Stock Options (Right to Buy)  $177.32                   (5) 8/8/2025  Common Stock  9786    9786  D 
 
Restricted Stock Units   (3)                  (9)  (9) Common Stock  1969    1969  D 
 
Stock Options (Right to Buy)  $190.41                   (9) 8/7/2026  Common Stock  9968    9968  D 
 
Stock Options (Right to Buy)  $190.41                   (7) 8/7/2026  Common Stock  13290    13290  D 
 

Explanation of Responses:
(1)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.0500 to $260.0400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(2)  The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.0800 to $261.0400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3)  Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(4)  Fully exercisable.
(5)  Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
(6)  Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.
(7)  Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
(8)  Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020.
(9)  Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(10)  Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(11)  Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Furlow Brenda S.
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN 55413


SVP - General Counsel

Signatures
/s/ Andrew Nick as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed. 6/1/2020
**Signature of Reporting Person Date
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Bio Techne Charts.
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Bio Techne Charts.